# Onconova Therapeutics Inc. (ONTX)

Source: https://www.quantisnow.com/company/ONTX
Generated: 2026-11-18T08:27:08.125Z

- Ticker: ONTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2013
- Website: onconova.com

## About

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

## Latest ONTX news and filings

- 2024-04-29 20:06 UTC [SEC Form 10-K] [SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-10-ka-filed-by-onconova-therapeutics-inc-amendment-5441014)
- 2024-04-16 20:15 UTC [SEC Form D] [SEC Form D filed by Onconova Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-onconova-therapeutics-inc-5413405)
- 2024-04-16 20:09 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Onconova Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-onconova-therapeutics-inc-5413311)
- 2024-04-16 20:06 UTC [SEC Form 8-K] [Onconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/onconova-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-5413277)
- 2024-04-12 20:11 UTC [SEC Form 3] [New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)](https://www.quantisnow.com/insight/new-insider-orbimed-advisors-llc-claimed-ownership-of-1045261-shares-5408245)
- 2024-04-11 21:41 UTC [SEC Form 3] [New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)](https://www.quantisnow.com/insight/new-insider-tpav-llc-claimed-ownership-of-1222738-shares-sec-5406621)
- 2024-04-09 01:37 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Onconova Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-onconova-therapeutics-inc-5398737)
- 2024-04-04 00:07 UTC [SEC Form 4] [Redfield Robert was granted 97,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/redfield-robert-was-granted-97500-shares-sec-form-4-5390676)
- 2024-04-04 00:04 UTC [SEC Form 4] [Pauza Charles David was granted 97,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/pauza-charles-david-was-granted-97500-shares-sec-form-4-5390669)
- 2024-04-04 00:03 UTC [SEC Form 4] [Cautreels Werner was granted 200,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/cautreels-werner-was-granted-200000-shares-sec-form-4-5390662)
- 2024-04-04 00:01 UTC [SEC Form 4] [Savchuk Nikolay was granted 2,664,869 shares (SEC Form 4)](https://www.quantisnow.com/insight/savchuk-nikolay-was-granted-2664869-shares-sec-form-4-5390646)
- 2024-04-03 23:59 UTC [SEC Form 4] [Dukes Iain D. was granted 1,779,337 shares (SEC Form 4)](https://www.quantisnow.com/insight/dukes-iain-d-was-granted-1779337-shares-sec-form-4-5390623)
- 2024-04-03 23:57 UTC [SEC Form 3] [New insider Viriom, Inc. claimed ownership of 1,645,100 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-viriom-inc-claimed-ownership-of-1645100-shares-sec-5390615)
- 2024-04-03 23:56 UTC [SEC Form 3] [New insider Orbimed Advisors Llc claimed ownership of 885,532 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-orbimed-advisors-llc-claimed-ownership-of-885532-shares-5390612)
- 2024-04-03 23:55 UTC [SEC Form 3] [SEC Form 3 filed by new insider Redfield Robert](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-redfield-robert-5390605)
- 2024-04-03 23:54 UTC [SEC Form 3] [SEC Form 3 filed by new insider Pauza Charles David](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-pauza-charles-david-5390599)
- 2024-04-03 23:53 UTC [SEC Form 3] [SEC Form 3 filed by new insider Cautreels Werner](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-cautreels-werner-5390595)
- 2024-04-03 23:51 UTC [SEC Form 3] [New insider Tpav, Llc claimed ownership of 885,532 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-tpav-llc-claimed-ownership-of-885532-shares-sec-5390591)
- 2024-04-03 23:50 UTC [SEC Form 3] [SEC Form 3 filed by new insider Savchuk Nikolay](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-savchuk-nikolay-5390588)
- 2024-04-03 23:47 UTC [SEC Form 3] [SEC Form 3 filed by new insider Dukes Iain D.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-dukes-iain-d-5390580)
- 2024-04-02 15:53 UTC [Market Chatter] [Onconova Therapeutics shares are trading lower after the company announced that it entered into a definitive merger agreement to acquire 100% of Trawsfynydd's outstanding equity interests.](https://www.quantisnow.com/insight/onconova-therapeutics-shares-are-trading-lower-after-the-company-announced-5383807)
- 2024-04-02 11:15 UTC [Traws Pharma Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/traws-pharma-announces-new-employee-inducement-grants-5382759)
- 2024-04-02 11:13 UTC [Market Chatter] [Onconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce All-Stock Business Combination, Under Agreement, Onconova Acquired 100% Of Trawsfynydd's Outstanding Equity Shares With A Combined Fully Diluted Equity Value Of $132M; In Connection, Traws Will Raise $14M In Committed Private Placement Financing](https://www.quantisnow.com/insight/onconova-therapeutics-inc-and-trawsfynydd-therapeutics-inc-announce-all-stock-business-5382754)
- 2024-04-02 11:00 UTC [Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company](https://www.quantisnow.com/insight/onconova-therapeutics-inc-and-trawsfynydd-therapeutics-inc-announce-business-combination-5382661)
- 2024-04-01 20:08 UTC [SEC Form 10-K] [SEC Form 10-K filed by Onconova Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-onconova-therapeutics-inc-5380770)
- 2024-03-15 21:40 UTC [SEC Form 4] [Guerin Mark Patrick converted options into 8,666 shares and covered exercise/tax liability with 2,591 shares, increasing direct ownership by 20% to 35,976 units (SEC Form 4)](https://www.quantisnow.com/insight/guerin-mark-patrick-converted-options-into-8666-shares-and-covered-5349041)
- 2024-03-15 21:36 UTC [SEC Form 4] [Fruchtman Steven M converted options into 23,111 shares and covered exercise/tax liability with 8,727 shares, increasing direct ownership by 24% to 74,792 units (SEC Form 4)](https://www.quantisnow.com/insight/fruchtman-steven-m-converted-options-into-23111-shares-and-covered-5349032)
- 2024-03-08 13:00 UTC [Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024](https://www.quantisnow.com/insight/onconova-therapeutics-rigosertib-poster-selected-for-aacr-2024-5329124)
- 2024-02-15 21:31 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-after-market-session-5268386)
- 2024-02-09 22:38 UTC [SEC Form 4] [Guerin Mark Patrick converted options into 6,900 shares and covered exercise/tax liability with 2,443 shares, increasing direct ownership by 18% to 29,901 units (SEC Form 4)](https://www.quantisnow.com/insight/guerin-mark-patrick-converted-options-into-6900-shares-and-covered-5247391)
- 2024-02-09 22:36 UTC [SEC Form 4] [Fruchtman Steven M covered exercise/tax liability with 9,212 shares and converted options into 21,320 shares, increasing direct ownership by 25% to 60,408 units (SEC Form 4)](https://www.quantisnow.com/insight/fruchtman-steven-m-covered-exercisetax-liability-with-9212-shares-and-5247387)
- 2023-12-12 13:12 UTC [Market Chatter] [Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity In Treatment Resistant Mantle Cell Lymphoma](https://www.quantisnow.com/insight/onconova-therapeutics-narazaciclib-ash-poster-highlights-activity-in-treatment-resistant-5131885)
- 2023-12-12 13:00 UTC [Market Insight] [Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-icosavax-shares-are-trading-higher-by-around-45-here-5131750)
- 2023-12-12 13:00 UTC [Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma](https://www.quantisnow.com/insight/onconova-therapeutics-narazaciclib-ash-poster-highlights-activity-in-treatment-resistant-5131740)
- 2023-12-11 21:31 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-after-market-session-5130537)
- 2023-12-11 18:12 UTC [Market Insight] [Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session](https://www.quantisnow.com/insight/why-bluebird-bio-shares-are-trading-higher-here-are-other-5129900)
- 2023-12-11 13:06 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-pre-market-session-5129082)
- 2023-12-11 12:59 UTC [Market Insight] [Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-green-giant-shares-are-trading-lower-by-around-37-5128984)
- 2023-12-08 21:30 UTC [Market Insight] [12 Health Care Stocks Moving In Friday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-fridays-after-market-session-5127823)
- 2023-12-08 21:05 UTC [Market Chatter] [Onconova Therapeutics' Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's](https://www.quantisnow.com/insight/onconova-therapeutics-preclinical-narazaciclib-data-at-sabcs-highlights-differentiated-anti-tumor-5127527)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ONTX
- Earnings history: https://www.quantisnow.com/earnings/ONTX
- Dividend history: https://www.quantisnow.com/dividends/ONTX
- Insider transactions: https://www.quantisnow.com/insiders/ONTX
- Options chain: https://www.quantisnow.com/options/ONTX
- SEC 8-K filings only: https://www.quantisnow.com/company/ONTX/8-k
- RSS and alerts for ONTX: https://www.quantisnow.com/docs/rss-feeds.md
